Cumberland Partners’s AbbVie ABBV Stock Holding History

Cumberland Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.7M	Buy	46,647 +21,140	+83%	+$4.55M	0.76%	39
2026 Q1	$5.55M	Sell	25,507 -14,525	-36%	-$3.22M	0.42%	41
2025 Q4	$9.15M	Sell	40,032 -4,200	-9%	-$957K	0.56%	39
2025 Q3	$10.2M	Buy	44,232 +19,130	+76%	+$3.9M	0.67%	32
2025 Q2	$4.66M	Buy	25,102 +1,545	+7%	+$287K	0.32%	58
2025 Q1	$4.94M	Buy	23,557 +4,175	+22%	+$812K	0.38%	52
2024 Q4	$3.44M	Sell	19,382 -8,615	-31%	-$1.58M	0.24%	67
2024 Q3	$5.53M	Sell	27,997 -14,850	-35%	-$2.77M	0.38%	54
2024 Q2	$7.35M	Buy	42,847 +14,395	+51%	+$2.38M	0.53%	42
2024 Q1	$5.18M	Buy	+28,452	New	+$4.9M	0.38%	55
2023 Q3	–	Sell	-20,262	Closed	-$2.73M	–	172
2023 Q2	$2.73M	Buy	20,262 +14,560	+255%	+$2.14M	0.25%	75
2023 Q1	$909K	Sell	5,702 -30,790	-84%	-$4.71M	0.09%	108
2022 Q4	$5.9M	Sell	36,492 -16,980	-32%	-$2.6M	0.62%	35
2022 Q3	$7.18M	Buy	53,472 +10,085	+23%	+$1.45M	0.76%	33
2022 Q2	$6.65M	Buy	43,387 +20,925	+93%	+$3.2M	0.63%	41
2022 Q1	$3.64M	Buy	22,462 +14,012	+166%	+$2.04M	0.28%	70
2021 Q4	$1.14M	Buy	+8,450	New	+$998K	0.08%	122
2019 Q1	–	Sell	-7,000	Closed	-$645K	–	162
2018 Q4	$645K	Buy	7,000 +115	+2%	+$10.1K	0.07%	117
2018 Q3	$651K	Sell	6,885 -7,650	-53%	-$725K	0.06%	125
2018 Q2	$1.35M	Buy	+14,535	New	+$1.42M	0.14%	91

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cumberland Partners's ABBV Position: Q2 2026 in Review

Cumberland Partners increased its AbbVie (ABBV) stake by 83% in Q2 2026, buying an estimated $4.55M and bringing the position to 46,647 shares worth $11.7M. The position accounts for 0.76% of the portfolio, ranked #39.

Cumberland Partners first reported a position in ABBV in Q2 2018 and has held it in 20 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cumberland Partners held 46,647 shares of AbbVie worth $11.7M as of Q2 2026.
Cumberland Partners bought 21,140 AbbVie shares in Q2 2026, an estimated $4.55M.
AbbVie made up 0.76% of Cumberland Partners's portfolio in Q2 2026, its #39 holding.
Cumberland Partners first reported a position in AbbVie in Q2 2018 and has held it in 20 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cumberland Partners's 13F filing for Q2 2026, filed 6 Aug 2026.